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We investigated the in vitro activity of a new antifuingal triazole, D0870, against 100 Candida albicans isolates
from the oral cavities of patients infected with human immunodeficiency virus by using a broth macrodilution
method following the recommendations provided by the National Committee for Clinical Laboratory
Standards (document M27-P). All of the isolates were chosen from C. albicans isolates already tested for
fluconazole susceptibility by the procedure of the National Committee for Clinical Laboratory Standards. Fifty
isolates were considered fluconazole susceptible (MICs, s4 ,ug/ml), and 50 isolates were considered
fluconazole resistant (MICs, .8 ,ig/ml). The in vitro data demonstrated that D0870 had good activity against
isolates tested; for 90%o of all strains of C. albicans, MICs were 0.5 ,ug/ml. However, the D0870 MICs for the
fluconazole-susceptible isolates were lower than those for the fluconazole-resistant isolates; MICs for 50 and
90%o of the isolates tested were .0.0078 and 0.06 ,ug/ml, respectively, for fluconazole-susceptible isolates and
0.25 and 2 ,Ig/ml, respectively, for fluconazole-resistant isolates (P <0.001). Our data suggest that this new
triazole could represent a valid alternative in the treatment of oral candidiasis in human immunodeficiency
virus-infected patients.
D0870 is a new antifungal triazole that is the (+) enantiomer
of ICI 195,739. D0870 has been reported in the literature to
have good in vitro activity against different species of yeasts,
molds, and dimorphic fungi (4, 8, 10, 21). No data are available
about its in vitro activity against Candida albicans isolates from
the oral cavities of human immunodeficiency virus (HIV)-
infected patients. In the last few years the development of
fluconazole-resistant isolates of C. albicans in these patients
has been reported (3, 5, 11, 15, 19). The lack of standardized
methods for in vitro antifungal susceptibility testing presents
difficulties in recognizing isolates with reduced susceptibilities
to the antifungal agents (12, 13). The Subcommittee on
Antifungal Susceptibility Testing of the National Committee
for Clinical Laboratory Standards (NCCLS) has recently pro-
posed a broth macrodilution reference method for the suscep-
tibility testing of yeasts (9). In the present study, we investi-
gated the in vitro activity of D0870 against 100 C. albicans
isolates from the oral cavities of HIV-infected patients by using
the proposed NCCLS procedure.
MATERUILS AND METHODS
Drug. D0870 (Zeneca Pharmaceuticals, Macclesfield,
United Kingdom) was obtained as a standard powder. A stock
solution of 5,000 ,ug/ml was prepared in polyethylene glycol
400 (Union Carbide, Danbury, Conn.) with the aid of heating
at 75°C for 30 min.
Isolates. One hundred isolates of C. albicans recovered from
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the oral cavities of HIV-infected patients were used in the
study. Each strain represented a unique isolate from a patient.
All of the strains were chosen from among C. albicans isolates
already tested for fluconazole susceptibility by the NCCLS
procedure (9). In order to obtain isolates of C. albicans with
different patterns of in vitro susceptibility to fluconazole, we
included 50 isolates for which the fluconazole MICs were s4
,ug/ml, which were considered susceptible (group A), and 50
isolates for which the fluconazole MICs were .8 p,g/ml, which
were considered resistant (group B) (Fig. 1). All of the isolates
were tested for susceptibility to D0870 in a blind and random
fashion by a broth macrodilution method following the recom-
mendations provided by NCCLS (9). Two reference strains, C.
albicans ATCC 90029, and Candida krusei 93-1380 (an isolate
from the collection of the Fungus Testing Laboratory, Depart-
ment of Pathology, University of Texas Health Science Center
at San Antonio), were included in each run of the experiments.
Susceptibility testing procedure. In the present study, RPMI
1640 (American Biorganics, Inc., Niagara Falls, N.Y.) medium
with L-glutamine without sodium bicarbonate and buffered at
pH 7 with morpholinepropanesulfonic acid (0.165 M; 46.5
g/liter) was used. Drug dilutions were prepared at 10 times the
strength of the final drug concentration (160 to 0.078 pLg/ml) by
a serial drug dilution schema for minimizing systematic pipet-
ting errors. The drugs were stored at -70°C until they were
used. The yeast inocula were spectrophotometrically prepared
as described in the NCCLS document (9). Confirmation of the
final inoculum size (in CFU per milliliter) was determined for
all test and control organisms by subcultures on Sabouraud
dextrose agar. Yeast inocula (0.9 ml) were added to 10 times
the strength of the final drug concentrations in polystyrene
plastic tubes (12 by 75 mm; Falcon 2054; Becton Dickinson,
Lincoln Park, N.J.), bringing the drug dilutions to the final test
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FIG. 1. Distribution of fluconazole MICs for 100 isolates of C. albicans tested by the NCCLS procedure (9). Gray bars indicate isolates
considered fluconazole susceptible (MICs, c4 ,ug/ml; group A); black bars indicate isolates considered fluconazole resistant (MICs, .8 ,ug/ml;
group B).
concentrations (0.0078 to 16 ,ug/ml). Drug-free and yeast-free
control tubes were included for each isolate tested. All tubes
were incubated without agitation at 35°C and were read at 48
h. Each tube was vortexed, and its turbidity was compared with
that of the drug-free growth control tube. The MIC was
defined as the lowest concentration which resulted in a visual
turbidity of less than or equal to 80% inhibition when com-
pared with that produced by the growth control (0.2 ml of
growth control plus 0.8 ml of uninoculated RPMI 1640) (9).
Statistical analysis. The significance of the differences in the
D0870 MIC distributions between isolates of the A and B
groups was determined by the Mann-Whitney U test.
RESULTS
All of the organisms tested produced detectable growth after
48 h of incubation. The inoculum sizes of the working suspen-
sions fell within the range reported by the NCCLS document
(0.5 x 103 to 2.5 x 103 CFU/ml) for all pathogenic yeasts and
the two reference isolates of Candida spp. (9). D0870 MICs for
C. albicans ATCC 90029 and C. krusei 93-1380 were <0.0078
and 2 ,ug/ml, respectively (Table 1). Figure 2 reveals the
distribution of D0870 MICs for the 100 clinical isolates of C.
albicans. D0870 MICs ranged from s0.0078 to 2 jig/ml, with
the MICs for 50% (MIC50s) and 90% (MIC90s) of the isolates
being 0.06 and 0.5 ,ug/ml, respectively. However, there was a
substantially different distribution of D0870 MICs between the
A and the B groups of C. albicans isolates (Fig. 2). D0870
MICs ranged from '0.0078 to 0.125 ,ug/ml for group A
isolates, with MIC50s and MIC90s of s0.0078 and 0.06 ,ug/ml,
respectively (Table 1). D0870 MICs ranged from .0.0078 to 2
i,g/ml for group B isolates, with MIC50s and MIC90s of 0.25
and 2 ,ug/ml, respectively (Table 1). When the Mann-Whitney
U test was applied to determine the distribution of D0870
MICs for the two groups of isolates, a statistically significant
difference was found (P <0.001).
DISCUSSION
In the present study we investigated the in vitro activity of a
new antifungal triazole, D0870, against C. albicans isolates
from the oral cavities of HIV-infected individuals. Although
the in vitro method for susceptibility testing of yeasts proposed
by NCCLS was developed only for flucytosine, amphotericin B,
ketoconazole, and fluconazole, we applied the same procedure
for testing D0870. Recently, Peng and Galgiani (10) studied
the effects of different assay conditions on the activity of D0870
against seven species of fungi using the broth macrodilution
method proposed by NCCLS (9). Interestingly, they found that
test conditions in keeping with NCCLS guidelines indeed
distinguished isolates of C. albicans and Cryptococcus neofor-
mans as susceptible when compared with the results for C.
krusei and Torulopsis glabrata. Our findings corroborate those
reported by those investigators. In testing 50 isolates of
TABLE 1. D0870 MICs for 100 clinical isolates of C. albicans and
two reference control organisms
MIC (Rg/ml)
Isolate (no.)
Range 50% 90%
C. albicans, group A (50) .0.0078-0.125 .0.0078 0.06
C. albicans, group B (50) -0.0078-2 0.25 2
C. albicans ATCC 90029a s0.0078
C. kusei 93-1380a 2
a Both of the reference control organisms were tested in 25 different sets of
experiments.
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FIG. 2. Distribution of D0870 MICs for 100 isolates of C. albicans tested by the NCCLS procedure (9). Gray and black bars indicate the
distributions of D0870 MICs for group A and B isolates, respectively.
fluconazole-susceptible C. albicans, we found that D0870
MIC50s and MIC90s were c0.0078 and 0.06 jig/ml, respec-
tively, which are values very close to those reported by Peng
and Galgiani (10). In addition, we found that for isolates for
which fluconazole MICs were high, D0870 MICs were propor-
tionally higher. The 10 isolates of the present series for which
the D0870 MIC was 2 ,ug/ml were highly resistant to flucon-
azole; fluconazole MICs were .64 ,g/ml. Interestingly, the
MIC of 2 ,ug/ml for D0870 is very close to the susceptibility
patterns reported by Peng and Galgiani (10) for C. kwusei and
T. glabrata, two species with frequently reported in vitro as well
in vivo azole resistance (1, 18, 20). Our results confirm those
previously reported from the testing of itraconazole against
fluconazole-susceptible and -resistant C albicans isolates in
this group of patients (2). Some of the isolates tested in the
present study were previously tested with itraconazole. For
those isolates for which fluconazole MICs were high, MICs of
itraconazole were high as well.
This phenomenon may be due to the fact that all azoles may
have same mechanism of action. Thus far, two mechanisms for
the reduced susceptibility of C. albicans to azole antifungal
agents have been described. One is due to changes in the
membrane sterol composition which cause a reduced level of
permeability of the C. albicans membrane to the drugs; the
second is due to a mutation of sterol 14a-demethylase, a
cytochrome P450 enzyme, that results in decreased binding
affinity for the azole drugs (6, 7, 14, 16). Recently, Vanden
Bossche et al. studied an isolate of T glabrata that was
clinically resistant to fluconazole. They showed that the re-
duced level of susceptibility to fluconazole was due either to
lower fluconazole uptake or to the increased level of P450-
dependent ergosterol synthesis of the fluconazole-resistant
isolate compared with that of the parental strain. Only the
increased ergosterol synthesis caused itraconazole cross-resis-
tance (17). The clinical consequences of this in vitro phenom-
enon are unclear. It is unknown whether treatment of patients
with oral candidiasis caused by fluconazole-resistant C. albi-
cans isolates with another azole fails or is resolved by an
increase in the azole dosage because of the lack of clinical
trials. In addition, it is difficult to correlate the in vitro data
with the clinical outcome in these patients, in whom the failure
of therapy for oral candidiasis may be due either to the
presence of C. albicans isolates resistant to the drugs or to the
immunodeficient state of the host. In conclusion, our findings
indicate that D0870 could represent a valid alternative in the
treatment of oral candidiasis in HIV-infected patients. It
remains to be seen whether concentrations of this new anti-
fungal triazole of 2 p,g/ml are potentially therapeutic since
there are no data available on the concentrations of the drug in
the tissue and serum of humans. Additional in vivo and in vitro
studies are warranted to further elucidate the potential anti-
fungal activity of this compound in HIV-infected patients.
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